# Comprehensive analysis of the potential effect and mechanism of pyroptosis-related genes in treatment-related myeloid tumors

**Authors:** Jing Cheng, Weiyue Fang, Hongxia Tan, Xiaoxia Zhan, Xiaohui Zhu, Kota Ramana, Kota Ramana, Kota Ramana, Kota Ramana

PMC · DOI: 10.1371/journal.pone.0343525 · PLOS One · 2026-02-24

## TL;DR

This study explores how pyroptosis-related genes might influence treatment-related myeloid tumors in mice, identifying key genes and pathways for future research.

## Contribution

The study presents a novel exploratory analysis of pyroptosis-related genes in a murine model of treatment-related myeloid neoplasms.

## Key findings

- 46 pyroptosis-related differentially expressed genes were identified, linked to autophagy, inflammation, and signaling pathways.
- Five hub genes (Trp53, Mtor, Gpx3, Foxo3, Cybb) showed high diagnostic accuracy in distinguishing t-MN from controls.
- Immune cell infiltration patterns correlated with hub gene expression, suggesting a role in tumor-immune interactions.

## Abstract

Treatment-related myeloid neoplasms (t-MN) represent a severe complication of cancer therapy, characterized by poor prognosis and limited treatment options. This study presents a preliminary, exploratory bioinformatic analysis aimed at characterizing the expression landscape and potential regulatory roles of pyroptosis-related genes (PRGs) in a murine model of t-MN. Utilizing RNA-seq data (GEO: GSE135866), differential expression analysis identified 1286 DEGs. Cross-referencing 367 curated mouse PRGs revealed 46 pyroptosis-related DEGs (PRDEGs). Functional enrichment analysis (GO, KEGG) showed these PRDEGs are significantly involved in autophagy, inflammatory regulation, apoptosis, NOD-like receptor signaling, and the AMPK pathway. GSEA associated the broader gene set with PI3K-Akt and Notch signaling. Protein-protein interaction network analysis identified five critical hub genes: Trp53, Mtor, Gpx3, Foxo3, and Cybb. ROC curve analysis confirmed these hub genes exhibit significant differential expression and high diagnostic accuracy (AUC > 0.9) in distinguishing t-MN from controls. Furthermore, immunoinfiltration analysis (CIBERSORT) revealed significant differences in immune cell composition between t-MN and control samples and identified notable correlations between hub gene expression and specific immune cell abundances. Importantly, given the limited sample size and the use of murine bone marrow data, the statistical findings should be interpreted strictly at the exploratory and hypothesis-generating level. This study does not support definitive biological conclusions or causal inferences but rather aims to delineate the pyroptosis-related molecular profile in a preclinical t-MN model. The results are intended to inform and guide future investigations—including validation in larger cohorts, independent experimental models, and human clinical samples—to assess the translational potential of these candidate biomarkers and therapeutic targets.

## Linked entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475], GPX3 (glutathione peroxidase 3) [NCBI Gene 2878], FOXO3 (forkhead box O3) [NCBI Gene 2309], CYBB (cytochrome b-245 beta chain) [NCBI Gene 1536]

## Full-text entities

- **Genes:** IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, Cybb (cytochrome b-245, beta polypeptide) [NCBI Gene 13058] {aka CGD91-phox, Cgd, Cyd, Nox2, gp91-1, gp91phox}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, SETD7 (SET domain containing 7, histone lysine methyltransferase) [NCBI Gene 80854] {aka KMT7, SET7, SET7/9, SET9}, TET2 (tet methylcytosine dioxygenase 2) [NCBI Gene 54790] {aka IMD75, KIAA1546, MDS}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, Gpx3 (glutathione peroxidase 3) [NCBI Gene 14778] {aka EGPx, GPx, GSHPx-3, GSHPx-P}, CYBB (cytochrome b-245 beta chain) [NCBI Gene 1536] {aka AMCBX2, CGD, CGDX, GP91-1, GP91-PHOX, GP91PHOX}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Trp53 (transformation related protein 53) [NCBI Gene 22059] {aka Tp53, bbl, bfy, bhy, p44, p53}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, Apc (APC, WNT signaling pathway regulator) [NCBI Gene 11789] {aka CC1, Min, mAPC}, BAK1 (BCL2 antagonist/killer 1) [NCBI Gene 578] {aka BAK, BAK-LIKE, BCL2L7, CDN1}, GPX3 (glutathione peroxidase 3) [NCBI Gene 2878] {aka GPx-P, GSHPx-3, GSHPx-P}, NOTCH4 (notch receptor 4) [NCBI Gene 4855] {aka INT3}, PIF1 (PIF1 5'-to-3' DNA helicase) [NCBI Gene 80119] {aka C15orf20, PIF}, PRKAB1 (protein kinase AMP-activated non-catalytic subunit beta 1) [NCBI Gene 5564] {aka AMPK, HAMPKb}, EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) [NCBI Gene 2146] {aka ENX-1, ENX1, EZH2b, KMT6, KMT6A, WVS}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, FOXO3 (forkhead box O3) [NCBI Gene 2309] {aka AF6q21, FKHRL1, FKHRL1P2, FOXO2, FOXO3A}, SPTAN1 (spectrin alpha, non-erythrocytic 1) [NCBI Gene 6709] {aka DEE5, DEVEP, EIEE5, HMN11, HMND11, NEAS}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, DNMT3A (DNA methyltransferase 3 alpha) [NCBI Gene 1788] {aka DNMT3A2, HESJAS, M.HsaIIIA, TBRS}, Bcl2l1 (BCL2-like 1) [NCBI Gene 12048] {aka Bcl(X)L, Bcl-XL, Bcl2l, BclX, bcl-x, bcl2-L-1}, CHMP4B (charged multivesicular body protein 4B) [NCBI Gene 128866] {aka C20orf178, CHMP4A, CTPP3, CTRCT31, SNF7, SNF7-2}, Foxo3 (forkhead box O3) [NCBI Gene 56484] {aka 1110048B16Rik, 2010203A17Rik, FKHRL1, Fkhr2, Foxo3a}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, Egr1 (early growth response 1) [NCBI Gene 13653] {aka A530045N19Rik, ETR103, Egr-1, Krox-1, Krox-24, Krox24}
- **Diseases:** leukemia (MESH:D007938), PRDEGs (MESH:D001039), myeloid disorders (MESH:D007951), focal death (MESH:D003643), metastasis (MESH:D009362), inflammation (MESH:D007249), ORCID iD (MESH:C535742), toxicities (MESH:D064420), t (OMIM:613700), Neoplasms (MESH:D009369), chromosomal abnormalities (MESH:D002869), t-MN (MESH:D016609), infection (MESH:D007239), focal (MESH:D005490), non-small-cell lung cancer (MESH:D002289), Blood Cancer (MESH:D019337), MDS (MESH:D009190), Diabetic Nephropathy (MESH:D003928), AML (MESH:D015470)
- **Chemicals:** ENU (MESH:D005038), t (MESH:D014316), -50021R1 (-), EA (MESH:D004976), MN (MESH:D008345), Lysophosphatidic Acid (MESH:C032881)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** LM22 — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_A1IU), t-MN — Mus musculus (Mouse), Mouse myeloid leukemia, Cancer cell line (CVCL_2107), C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU), /6 — Homo sapiens (Human), Tongue squamous cell carcinoma, Cancer cell line (CVCL_5985), PONE-D-25-50021 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_1E77), EA — Homo sapiens (Human), Transformed cell line (CVCL_E575)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12931785/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12931785/full.md

## References

66 references — full list in the complete paper: https://tomesphere.com/paper/PMC12931785/full.md

---
Source: https://tomesphere.com/paper/PMC12931785